Search Results for "actinic"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for actinic. Results 1 to 3 of 3 total matches.
Tirbanibulin 1% Ointment (Klisyri) for Actinic Keratosis
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
Tirbanibulin 1% Ointment (Klisyri) for Actinic Keratosis ...
Tirbanibulin, a microtubule inhibitor, has been
approved by the FDA as a 1% ointment (Klisyri –
Almirall) for topical treatment of actinic keratosis of
the face or scalp.
Mavacamten (Camzyos) for Obstructive Hypertrophic Cardiomyopathy
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
); it decreases myosin cross-bridge formation
with actin, which reduces cardiac contractility and
leads ...
The FDA has approved mavacamten (Camzyos –
MyoKardia/BMS), a modulator of cardiac myosin, to
improve functional capacity and symptoms in adults
with New York Heart Association (NYHA) class II or
III obstructive hypertrophic cardiomyopathy (HCM)
who have a baseline left ventricular ejection fraction
(LVEF) ≥55%. Mavacamten is the first drug in its class
to become available in the US.
Treatment of Onychomycosis
The Medical Letter on Drugs and Therapeutics • Oct 18, 2021 (Issue 1635)
of actinic keratosis, has been used offlabel
for treatment of onychomycosis. It has been
associated ...
Onychomycosis is caused most commonly by
Trichophyton rubrum or T. mentagrophytes. About
10% of all persons worldwide and 40% of those ≥60
years old are believed to have the disease. Risk
factors include older age, diabetes, poor peripheral
circulation, smoking, HIV infection, psoriasis, and
immunosuppression. Left untreated, onychomycosis
can cause nail plate destruction, ingrown nails, and
(particularly in patients with diabetes) secondary
infections. Guidelines on treatment of onychomycosis
have been published.